Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

TH9507 in Patients With HIV-Associated Lipodystrophy

This study has been completed.
Information provided by:
Theratechnologies Identifier:
First received: July 20, 2005
Last updated: November 26, 2013
Last verified: November 2013
HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation and loss of extremity and subcutaneous fat, in association with dyslipidemia and insulin resistance. Data from a previous randomized, placebo-controlled trial demonstrated that daily administration of 2mg TH9507, a growth hormone releasing factor (GRF), to HIV patients with an excess of abdominal fat accumulation for 12 weeks resulted in decreases in visceral adipose tissue (VAT) and trunk fat, with no significant changes in limb fat and subcutaneous adipose tissue (SAT). This study is aimed at further assessing the efficacy and safety of 2 mg TH9507 in a larger population of HIV patients treated with ART and experiencing an excess of abdominal fat accumulation.

Condition Intervention Phase
HIV Infections
Drug: TH9507
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation

Resource links provided by NLM:

Further study details as provided by Theratechnologies:

Primary Outcome Measures:
  • Visceral adipose tissue (VAT)

Enrollment: 412
Study Start Date: June 2005
Study Completion Date: April 2007
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ages 18 to 65 years inclusive
  • HIV positive; CD4 cell counts >100 cells/mm3; viral load <10,000 copies/mL (stable for 8 weeks)
  • On stable ART regimen for at least 8 weeks prior to randomization
  • Have evidence of abdominal fat accumulation defined by the following anthropometric cut off values:

    • For males: waist circumference > 95 cm and waist to hip ratio > 0.94;
    • For females: waist circumference > 94 cm and waist to hip ratio > 0.88.
  • Females of childbearing potential not pregnant or lactating; normal mammography within 6 months of study.
  • Signed informed consent

Exclusion Criteria:

  • Body mass index < 20 kg/m2
  • Opportunistic infection; HIV-related disease within 3 months of study.
  • History of malignancy; active neoplasm.
  • Prostate-specific antigen (PSA) >5 ng/mL at screening
  • Hypopituitarism; history of pituitary tumor/surgery; head irradiation; head trauma that has affected the somatotropic axis.
  • Untreated hypothyroidism
  • Type 1 diabetics and type 2 diabetics on oral hypoglycemic or insulin sensitizing agent within 6 months of study
  • ALT or AST > 3 x ULN; serum creatinine > 133 mmol/L (1.5 mg/dL); hemoglobin more than 20 g/L below LLN; fasting blood glucose > 8.33 mmol/L (150 mg/dL); fasting triglycerides > 11.3 mmol/L (0.99 g/dL).
  • Untreated hypertension
  • Change in anti-hyperlipemic regimen within 3 months prior to study
  • Change in testosterone regimen and/or supraphysiological dose of testosterone
  • Estrogen therapy
  • Anoretics/anorexigenics or anti-obesity agents within 3 months of study
  • Growth hormone (GH); GH secretagogues; growth hormone releasing factor (GRF) products; IGF-1; or IGFBP-3 within 6 months of study.
  • Drug or alcohol dependence or use of methadone within 6 months of study entry
  • Participation in a clinical trial with any investigational drug/device within 30 days of screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00123253

  Hide Study Locations
United States, California
UCLA School of Medicine
Los Angeles, California, United States
Office of Dr. Michael Somero
Palm Springs, California, United States
UCSD Medical Center
San Diego, California, United States
Kaiser Permanente
San Francisco, California, United States
AIDS Research Alliance
West Hollywood, California, United States
United States, District of Columbia
Capital Medical Associates
Washington, District of Columbia, United States
United States, Florida
Bach & Godofsky
Bradenton, Florida, United States
Office of Dr. Gary Richmond
Ft. Lauderdale, Florida, United States
Care Resource Miami
Miami, Florida, United States
Orlando Immunology Center
Orlando, Florida, United States
Infectious Disease Associates
Sarasota, Florida, United States
Treasure Coast Infectious Disease Consultant (TDIDC)
Vero Beach, Florida, United States
United States, Georgia
AIDS Research Consortium Atlanta (ARCA)
Atlanta, Georgia, United States
United States, Illinois
Northern Healthcare
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
United States, Indiana
Indiana University Department of Medicine
Indianapolis, Indiana, United States
United States, Maryland
Institute of Human Virology
Baltimore, Maryland, United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
United States, Massachusetts
Community Research Initiative of New England
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Tufts University School of Medicine
Boston, Massachusetts, United States
Community Research Initiative of New England (CRI West)
Springfield, Massachusetts, United States
United States, Minnesota
Hennepin County Medical Centre
Minneapolis, Minnesota, United States
United States, New York
AIDS Community Research Initiative of America
New York, New York, United States
Bellevue Hospital Center New York University
New York, New York, United States
St Luke's Roosevelt Hospital Centre
New York, New York, United States
St Vincent Catholic Medical Centre
New York, New York, United States
United States, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
United States, Oregon
Fanno Creek Clinic, LLC
Portland, Oregon, United States
United States, Pennsylvania
Drexel University College of Medicine
Philadelphia, Pennsylvania, United States
United States, Texas
Central Texas Clinical Research
Austin, Texas, United States
Dallas VA Medical Centre
Dallas, Texas, United States
The University of Texas Medical School
Houston, Texas, United States
United States, Virginia
Infectious Disease Physicians Inc.
Annandale, Virginia, United States
United States, Washington
Swedish Medical Center
Seattle, Washington, United States
Canada, Alberta
Southern Alberta Clinic
Calgary, Alberta, Canada
Canada, British Columbia
St-Paul's Hospital
Vancouver, British Columbia, Canada
Canada, Ontario
Sunnybrook and Women College Health Sciences Centre
Toronto, Ontario, Canada
Windsor Regional Hospital
Windsor, Ontario, Canada
Canada, Quebec
Clinique Médicale du Quartier Latin
Montreal, Quebec, Canada
Clinique Médicale L'Actuel
Montreal, Quebec, Canada
Montreal General Hospital
Montreal, Quebec, Canada
Sponsors and Collaborators
Principal Investigator: Steven Grinspoon, MD Massachusetts General Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00123253     History of Changes
Obsolete Identifiers: NCT00435136
Other Study ID Numbers: TH9507/III/LIPO/010
Study First Received: July 20, 2005
Last Updated: November 26, 2013

Keywords provided by Theratechnologies:
Abdominal fat accumulation
Growth hormone releasing factor/Growth hormone releasing hormone
Treatment Experienced

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Skin Diseases, Metabolic
Skin Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Growth Hormone-Releasing Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on April 28, 2017